Advertisement
Advertisement
TIL
Instil Bio, Inc. Common Stock
7.38
USDSponsored
+0.11
+1.51%
Aug 14, 15:59 UTC -4
Closed
Pre-Market
7.37
-0.01
-0.14%
TIL Earnings Reports
Positive Surprise Ratio
TIL beat 8 of 21 last estimates.
38%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.33
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-83.50%
Instil Bio, Inc. Common Stock earnings per share and revenue
On Aug 11, 2026, TIL reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.43 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
Kyntra Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.24
Actual
-$4.68
Surprise
-44.15%
Biofrontera Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.05
Surprise
+53.31%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.11
Actual
$0.35
Surprise
+198.38%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Caribou Biosciences, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.32
Actual
-$0.24
Surprise
+25.74%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
FAQ
What were Instil Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Instil Bio, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Instil Bio, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Instil Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Instil Bio, Inc. Common Stock's next earnings report?
Based on 4
analysts, Instil Bio, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement